Search

Your search keyword '"Adetifa, Ifedayo"' showing total 14 results
Start Over Author "Adetifa, Ifedayo" Journal plos one
14 results on '"Adetifa, Ifedayo"'

1. SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: Implications for epidemic control

Author

Adeyemi, Oluwapelumi Olufemi, primary, Ndodo, Nnaemeka Darlington, additional, Sulaiman, Mariam Kehinde, additional, Ayansola, Oyeronke Temidayo, additional, Buhari, Oluwabunmi Idera Nimat, additional, Akanbi, Olusola Anuoluwapo, additional, Bolarinwa, Oladimeji Akeem, additional, Chukwu, Chimaobi, additional, Joel, Ireoluwa Yinka, additional, Omoare, Adesuyi Ayodeji, additional, Wahab, Kolawole Wasiu, additional, Obiekea, Celestina, additional, Buhari, Mikhail Olayinka, additional, Ahumibe, Anthony, additional, Kolawole, Caroline Folasade, additional, Okoi, Catherine, additional, Omotesho, Olumuyiwa Babagbemi, additional, Mba, Nwando, additional, Adeniyi, Oluwafemi, additional, Babatunde, Olajumoke, additional, Akintunde, Nathaniel, additional, Ayinla, Ganiu, additional, Akande, Oluwatosin Wuraola, additional, Odunola, Rasheed Adekeye, additional, Saka, Mohammed Jimoh, additional, Musa, Omotosho Ibrahim, additional, Durotoye, Idayat Adenike, additional, Ihekweazu, Chikwe, additional, Adetifa, Ifedayo Morayo, additional, and Fadeyi, Abayomi, additional

Published
2023
Full Text
View/download PDF

2. Epidemiological trends of Lassa fever in Nigeria, 2018–2021

Author

Dalhat, Mahmood M., primary, Olayinka, Adebola, additional, Meremikwu, Martin M., additional, Dan-Nwafor, Chioma, additional, Iniobong, Akanimo, additional, Ntoimo, Lorretta F., additional, Onoh, Ikenna, additional, Mba, Sandra, additional, Ohonsi, Cornelius, additional, Arinze, Chinedu, additional, Esu, Ekpereonne B., additional, Nwafor, Obinna, additional, Oladipupo, Ipadeola, additional, Onoja, Michael, additional, Ilori, Elsie, additional, Okonofua, Friday, additional, Ochu, Chinwe L., additional, Igumbor, Ehimario U., additional, and Adetifa, Ifedayo, additional

Published
2022
Full Text
View/download PDF

3. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21

Author

Lucinde, Ruth K., primary, Mugo, Daisy, additional, Bottomley, Christian, additional, Karani, Angela, additional, Gardiner, Elizabeth, additional, Aziza, Rabia, additional, Gitonga, John N., additional, Karanja, Henry, additional, Nyagwange, James, additional, Tuju, James, additional, Wanjiku, Perpetual, additional, Nzomo, Edward, additional, Kamuri, Evans, additional, Thuranira, Kaugiria, additional, Agunda, Sarah, additional, Nyutu, Gideon, additional, Etyang, Anthony O., additional, Adetifa, Ifedayo M. O., additional, Kagucia, Eunice, additional, Uyoga, Sophie, additional, Otiende, Mark, additional, Otieno, Edward, additional, Ndwiga, Leonard, additional, Agoti, Charles N., additional, Aman, Rashid A., additional, Mwangangi, Mercy, additional, Amoth, Patrick, additional, Kasera, Kadondi, additional, Nyaguara, Amek, additional, Ng’ang’a, Wangari, additional, Ochola, Lucy B., additional, Namdala, Emukule, additional, Gaunya, Oscar, additional, Okuku, Rosemary, additional, Barasa, Edwine, additional, Bejon, Philip, additional, Tsofa, Benjamin, additional, Ochola-Oyier, L. Isabella, additional, Warimwe, George M., additional, Agweyu, Ambrose, additional, Scott, J. Anthony G., additional, and Gallagher, Katherine E., additional

Published
2022
Full Text
View/download PDF

4. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol.

Author

Penfold, Suzanne, Adegnika, Ayola Akim, Asogun, Danny, Ayodeji, Olufemi, Azuogu, Benedict N., Fischer II, William A., Garry, Robert F., Grant, Donald Samuel, Happi, Christian, N'Faly, Magassouba, Olayinka, Adebola, Samuels, Robert, Sibley, Jefferson, Wohl, David A., Accrombessi, Manfred, Adetifa, Ifedayo, Annibaldis, Giuditta, Camacho, Anton, Dan-Nwafor, Chioma, and Deha, Akpénè Ruth Esperencia

Subjects
LASSA fever, DISEASE incidence, VACCINE trials, SENSORINEURAL hearing loss, COHORT analysis, PLANT viruses
Abstract

Background: Lassa fever (LF), a haemorrhagic illness caused by the Lassa fever virus (LASV), is endemic in West Africa and causes 5000 fatalities every year. The true prevalence and incidence rates of LF are unknown as infections are often asymptomatic, clinical presentations are varied, and surveillance systems are not robust. The aim of the Enable Lassa research programme is to estimate the incidences of LASV infection and LF disease in five West African countries. The core protocol described here harmonises key study components, such as eligibility criteria, case definitions, outcome measures, and laboratory tests, which will maximise the comparability of data for between-country analyses. Method: We are conducting a prospective cohort study in Benin, Guinea, Liberia, Nigeria (three sites), and Sierra Leone from 2020 to 2023, with 24 months of follow-up. Each site will assess the incidence of LASV infection, LF disease, or both. When both incidences are assessed the LASV cohort (nmin = 1000 per site) will be drawn from the LF cohort (nmin = 5000 per site). During recruitment participants will complete questionnaires on household composition, socioeconomic status, demographic characteristics, and LF history, and blood samples will be collected to determine IgG LASV serostatus. LF disease cohort participants will be contacted biweekly to identify acute febrile cases, from whom blood samples will be drawn to test for active LASV infection using RT-PCR. Symptom and treatment data will be abstracted from medical records of LF cases. LF survivors will be followed up after four months to assess sequelae, specifically sensorineural hearing loss. LASV infection cohort participants will be asked for a blood sample every six months to assess LASV serostatus (IgG and IgM). Discussion: Data on LASV infection and LF disease incidence in West Africa from this research programme will determine the feasibility of future Phase IIb or III clinical trials for LF vaccine candidates. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Incidence of Tuberculosis and the Predictive Value of ELISPOT and Mantoux Tests in Gambian Case Contacts

Author

Hill, Philip C., primary, Jackson-Sillah, Dolly J., additional, Fox, Annette, additional, Brookes, Roger H., additional, de Jong, Bouke C., additional, Lugos, Moses D., additional, Adetifa, Ifedayo M., additional, Donkor, Simon A., additional, Aiken, Alex M., additional, Howie, Stephen R., additional, Corrah, Tumani, additional, McAdam, Keith P., additional, and Adegbola, Richard A., additional

Published
2008
Full Text
View/download PDF

14. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort.

Author

Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, and Ota MO

Subjects
Adolescent, Africa, Western, Antigens, Bacterial immunology, Cohort Studies, Culture Media, Conditioned metabolism, Diagnosis, Differential, Humans, Latent Tuberculosis immunology, Male, Multivariate Analysis, Mycobacterium tuberculosis physiology, Recombinant Fusion Proteins immunology, Time Factors, Tuberculin immunology, Tuberculin Test, Young Adult, Interleukin-12 biosynthesis, Interleukin-17 biosynthesis, Latent Tuberculosis diagnosis, Latent Tuberculosis metabolism, Tumor Necrosis Factor-alpha biosynthesis
Abstract

Background: Mycobacterium tuberculosis (MTb) infects approximately 2 billion people world-wide resulting in almost 2 million deaths per year. Determining biomarkers that distinguish different stages of tuberculosis (TB) infection and disease will provide tools for more effective diagnosis and ultimately aid in the development of new vaccine candidates. The current diagnostic kits utilising production of IFN-gamma in response to TB antigens can detect MTb infection but are unable to distinguish between infection and disease. The aim of this study was to assess if the use of a longer term assay and the analysis of multiple cytokines would enhance diagnosis of active TB in a TB-endemic population., Methods: We compared production of multiple cytokines (TNF-alpha, IFN-gamma, IL-10, IL-12(p40), IL-13, IL-17 and IL-18) following long-term (7 days) stimulation of whole-blood with TB antigens (ESAT-6/CFP-10 (EC), PPD or TB10.4) from TB cases (n = 36) and their Mycobacterium-infected (TST+; n = 20) or uninfected (TST-; n = 19) household contacts (HHC)., Results and Conclusions: We found that TNF-alpha production following EC stimulation and TNF-alpha and IL-12(p40) following TB10.4 stimulation were significantly higher from TB cases compared to TST+ HHC, while production of IFN-gamma and IL-13 were significantly higher from TST+ compared to TST- HHC following PPD or EC stimulation. Combined analysis of TNF-alpha, IL-12(p40) and IL-17 following TB10.4 stimulation resulted in 85% correct classification into TB cases or TST+ HHC. 74% correct classification into TST+ or TST- HHC was achieved with IFN-gamma alone following TB10.4 stimulation (69% following EC) and little enhancement was seen with additional cytokines. We also saw a tendency for TB cases infected with M. africanum to have increased TNF-alpha and IL-10 production compared to those infected with M. tuberculosis. Our results provide further insight into the pathogenesis of tuberculosis and may enhance the specificity of the currently available diagnostic tests, particularly for diagnosis of active TB.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results